ESC 2015: Phase 2 data results to be revealed for first-in-class, single-dose gene therapy for congestive heart failure

August 25, 2015

At the European Society of Cardiology (ESC) Congress 2015 (Aug. 29 – Sept. 2), Dr. H. Kirk Hammond, co-founder of Renova Therapeutics, a professor of medicine at UC San Diego, and cardiologist at the Veterans Affairs San Diego Healthcare System, will announce Phase 2 clinical trial results of a first-in-class, single-dose gene therapy treatment for patients with reduced left ventricular ejection fraction (r-LVEF) congestive heart failure (CHF). The one-time treatment, known as RT-100, is designed to provide substantially improved, sustained outcomes in heart failure patients by improving heart function and enabling the heart to pump more effectively.

RT-100 is an investigational product that delivers a therapeutic gene encoding the protein AC6 (adenylyl cyclase type 6) directly to the heart tissue during a routine outpatient procedure – similar to an angiography – without the need for surgery. AC6 is a protein found in cardiac muscle cells that has many important roles in regulating heart function. Rather than slow progression or minimize symptoms of CHF, RT-100 has shown in animal studies the ability to halt and reverse the CHF-induced remodeling of the heart, enabling it to pump more effectively.

The data is anticipated to support more than a decade of intensive pre-clinical research showing the effects of RT-100 on chronically diseased hearts. The Phase 2 study was conducted with 56 patients in seven geographically distributed medical centers in the U.S. through a Public-Private Partnership between Renova Therapeutics and the NIH.

Dr. Hammond will present the clinical trial results at ESC in London on Tuesday, Sept. 1 at 3:00 p.m. UK/7:00 a.m. PT.

Media contact:

Senka Hadzimuratovic
Executive Director of Communications & Operations
senka@renovatherapeutics.com
858.754.6216

Subscribe to receive company press releases and announcements
*required